DAPK1 and colorectal cancer: This suggests that SIRT3 may serve as a therapeutic target in colorectal cancer.DAPK1 is almost unexpressed in poorly differentiated colorectal cancer cells and gradually decreases at the invasive front of colorectal cancer, further emphasizing its critical role in diminishing tumor cell migratory capabilit,60, 61.